Tom 7, Nr 6 (2021)
Wytyczne / stanowisko ekspertów
Opublikowany online: 2021-10-25
Wyświetlenia strony
3296
Wyświetlenia/pobrania artykułu
649
Leczenie chorych na zaawansowanego raka jelita grubego z mutacją w genie BRAFV600E
Onkol Prakt Klin Edu 2021;7(6):347-360.
Streszczenie
Postęp w zakresie rokowania chorych na raka jelita grubego jest między innymi związany z wprowadzaniem nowych metod systemowego leczenia ukierunkowanego molekularnie. Przykładem jest leczenie ukierunkowane chorych z mutacją BRAFV600E. Obecne stanowisko ekspertów zostało przygotowane w celu przedstawienia uwarunkowań genetycznych i diagnostycznych oraz możliwych do wykorzystania metod leczenia chorych na zaawansowanego raka jelita grubego z mutacją w genie BRAFV600E.
Słowa kluczowe: rak jelita grubegozaawansowane stadium chorobymutacja w genie BRAFleczenie systemowe
Referencje
- Nagy R, Sweet K, Eng C. Highly penetrant hereditary cancer syndromes. Oncogene. 2004; 23(38): 6445–6470.
- Garber JE, Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol. 2005; 23(2): 276–292.
- Stjepanovic N, Moreira L, Carneiro F, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019; 30(10): 1558–1571.
- McCartan D, Chatterjee S. Hereditary and familial cancer. Surgery (Oxford). 2018; 36(3): 145–150.
- Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21(11): 1350–1356.
- Inamura K. Colorectal Cancers: An Update on Their Molecular Pathology. Cancers (Basel). 2018; 10(1).
- Tie J, Desai J. Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies. Target Oncol. 2015; 10(2): 179–188.
- NCCN Clinical Practice Guidelines in Oncology. https://www.nccn.org/professionals/physician_gls/default.aspx (21.03.2020).
- Sveen A, Kopetz S, Lothe RA. Biomarker-guided therapy for colorectal cancer: strength in complexity. Nat Rev Clin Oncol. 2020; 17(1): 11–32.
- Siddiqui AD, Piperdi B. KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy. Ann Surg Oncol. 2010; 17(4): 1168–1176.
- Xie YH, Chen YX, Fang JY. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020; 5(1): 22.
- Jones J, Renfro L, Al-Shamsi H, et al. Non-V600BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. J Clin Oncol. 2017; 35(23): 2624–2630.
- Tran B, Kopetz S, Tie J, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011; 117(20): 4623–4632.
- Morris V, Overman MJ, Jiang ZQ, et al. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer. 2014; 13(3): 164–171.
- van Krieken JH, Jung A, Kirchner T, et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch. 2008; 453(5): 417–431.
- Dijkstra JR, Heideman DAM, Meijer GA, et al. KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance. Virchows Arch. 2013; 462(1): 39–46.
- Tsiatis AC, Norris-Kirby A, Rich RG, et al. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J Mol Diagn. 2010; 12(4): 425–432.
- Tol J, Dijkstra JR, Vink-Börger ME, et al. High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. J Cell Mol Med. 2010; 14(8): 2122–2131.
- Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016; 27(8): 1386–1422.
- Ebi H, Corcoran RB, Singh A, et al. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J Clin Invest. 2011; 121(11): 4311–4321.
- Dienstmann R, Connor K, Byrne AT, et al. COLOSSUS Consortium. Precision Therapy in RAS Mutant Colorectal Cancer. Gastroenterology. 2020; 158(4): 806–811.
- Margonis GA, Buettner S, Andreatos N, et al. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer. JAMA Surg. 2018; 153(7): e180996.
- Ma H, Brosens LAA, Offerhaus GJ, et al. Pathology and genetics of hereditary colorectal cancer. Pathology. 2018; 50(1): 49–59.
- Praca zbiorowa. Optymalizacja diagnostyki patomorfologicznej i molekularnej oraz leczenia raka płuca ICD10-C34. 2020.
- Praca zbiorowa. Wpływ zmiany finansowania badan diagnostycznych genetycznych na dostępność do terapii innowacyjnych. 2020.
- EQA colon 2017.
- French AJ, Sargent DJ, Burgart LJ, et al. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res. 2008; 14(11): 3408–3415.
- Kalady MF, Dejulius KL, Sanchez JA, et al. BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis. Dis Colon Rectum. 2012; 55(2): 128–133.
- Ogino S, Nosho K, Kirkner GJ, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2009; 58(1): 90–96.
- Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 2005; 65(14): 6063–6069.
- Chen D, Huang JF, Liu K, et al. BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis. PLoS One. 2014; 9(3): e90607.
- Ogino S, Nosho K, Kirkner GJ, et al. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol. 2009; 27(9): 1477–1484.
- Zarkavelis G, Boussios S, Papadaki A, et al. Current and future biomarkers in colorectal cancer. Ann Gastroenterol. 2017; 30(6): 613–621.
- Fariña-Sarasqueta A, van Lijnschoten G, Moerland E, et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol. 2010; 21(12): 2396–2402.
- Nakayama I, Hirota T, Shinozaki E. Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation. Cancers (Basel). 2020; 12(11).
- Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010; 28(3): 466–474.
- Ashktorab H, Ahuja S, Kannan L, et al. A meta-analysis of MSI frequency and race in colorectal cancer. Oncotarget. 2016; 7(23): 34546–34557.
- Phipps AI, Buchanan DD, Makar KW, et al. BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics. Cancer Epidemiol Biomarkers Prev. 2012; 21(10): 1792–1798.
- Phipps AI, Limburg PJ, Baron JA, et al. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology. 2015; 148(1): 77–87.e2.
- Bläker H, Alwers E, Arnold A, et al. The Association Between Mutations in BRAF and Colorectal Cancer-Specific Survival Depends on Microsatellite Status and Tumor Stage. Clin Gastroenterol Hepatol. 2019; 17(3): 455–462.e6.
- Taieb J, Le Malicot K, Shi Q, et al. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer. J Natl Cancer Inst. 2017; 109(5).
- Sinicrope FA, Shi Q, Allegra CJ, et al. Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Oncol. 2017; 3(4): 472–480.
- Ogino S, Shima K, Meyerhardt JA, et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res. 2012; 18(3): 890–900.
- Gavin PG, Colangelo LH, Fumagalli D, et al. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res. 2012; 18(23): 6531–6541.
- Schirripa M, Bergamo F, Cremolini C, et al. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. Br J Cancer. 2015; 112(12): 1921–1928.
- Kubota N, Taniguchi F, Nyuya A, et al. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability. J Hepatobiliary Pancreat Sci. 2013; 20(2): 223–233.
- Teng HW, Huang YC, Lin JK, et al. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy. J Surg Oncol. 2012; 106(2): 123–129.
- Johnson B, Jin Z, Truty MJ, et al. Impact of Metastasectomy in the Multimodality Approach for V600E Metastatic Colorectal Cancer: The Mayo Clinic Experience. Oncologist. 2018; 23(1): 128–134.
- Venderbosch S, Nagtegaal ID, Maughan TS, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res. 2014; 20(20): 5322–5330.
- Morris V, Overman MJ, Jiang ZQ, et al. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer. 2014; 13(3): 164–171.
- Loupakis F, Cremolini C, Salvatore L, et al. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Eur J Cancer. 2014; 50(1): 57–63.
- Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015; 16(13): 1306–1315.
- Cremolini C, Antoniotti C, Rossini D, et al. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treat- ment of patients with metastatic colorectal cancer (TRIBE2): a multi- centre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020; 21(4): 497–507.
- Cremolini C, Antoniotti C, Stein A, et al. FOLFOXIRI/bevacizumab (bev) versus doublets/bev as initial therapy of unresectable metastatic colorectal cancer (mCRC): A meta-analysis of individual patient data (IPD) from five randomized trials. J Clin Oncol. 2020; 38(15_suppl): 4015–4015.
- Ince WL, Jubb AM, Holden SN, et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst. 2005; 97(13): 981–989.
- Price TJ, Hardingham JE, Lee CK, et al. Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. J Clin Oncol. 2011; 29(19): 2675–2682.
- Wirapati P, Pomella V, Vandenbosch B, et al. Velour trial biomarkers update: Impact of RAS, BRAF, and sidedness on aflibercept activity. J Clin Oncol. 2017; 35(15_suppl): 3538–3538.
- Yoshino T, Obermannova R, Bodoky G, et al. Are BRAF mutated metastatic colorectal cancer (mCRC) tumors more responsive to VEGFR-2 blockage? Analysis of patient outcomes by RAS/RAF mutation status in the RAISE study—A global, randomized, double-blind, phase III study. J Clin Oncol. 2018; 36(4_suppl): 622–622.
- Douillard JY, Siena S, Cassidy J, et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol. 2014; 25(7): 1346–1355.
- Seymour MT, Brown SR, Middleton G, et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol. 2013; 14(8): 749–759.
- Bokemeyer C, Van Cutsem E, Rougier P, et al. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer. 2012; 48(10): 1466–1475.
- Pietrantonio F, Petrelli F, Coinu A, et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer. 2015; 51(5): 587–594.
- Rowland A, Dias MM, Wiese MD, et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer. 2015; 112(12): 1888–1894.
- Yoshino T, Arnold D, Taniguchi H, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol. 2018; 29(1): 44–70.
- NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Colon Cancer. Version 2. 2021.
- Stintzing S, Heinrich K, Tougeron D, et al. Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: The phase-II FIRE-4.5 study (AIO KRK-0116). J Clin Oncol. 2021; 39(15_suppl): 3502–3502.
- Yang H, Higgins B, Kolinsky K, et al. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res. 2012; 72(3): 779–789.
- Kopetz S, Desai J, Chan E, et al. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. J Clin Oncol. 2015; 33(34): 4032–4038.
- Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012; 483(7387): 100–103.
- Corcoran RB, Ebi H, Turke AB, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2012; 2(3): 227–235.
- Grothey A, Tabernero J, Taieb J, et al. LBA-5 ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer. Ann Oncol. 2020; 31: S242–S243.
- ClinicalTrials.gov Identifier: NCT 04607421.
- Seppälä TT, Böhm JP, Friman M, et al. Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer. Br J Cancer. 2015; 112(12): 1966–1975.
- Parsons MT, Buchanan DD, Thompson B, et al. Correlation of tumour BRAF mutations and MLH1 methylation with germline mismatch repair (MMR) gene mutation status: a literature review assessing utility of tumour features for MMR variant classification. J Med Genet. 2012; 49(3): 151–157.
- Lochhead P, Kuchiba A, Imamura Yu, et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst. 2013; 105(15): 1151–1156.
- Saridaki Z, Souglakos J, Georgoulias V. Prognostic and predictive significance of MSI in stages II/III colon cancer. World J Gastroenterol. 2014; 20(22): 6809–6814.
- Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017; 18(9): 1182–1191.
- Overman MJ, Lonardi S, Wong KaY, et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol. 2018; 36(8): 773–779.
- André T, Lonardi S, Wong K, et al. SO-27 Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. Ann Oncol. 2021; 32: S213–S214.
- André T, Shiu KK, Kim TW, et al. KEYNOTE-177 Investigators. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med. 2020; 383(23): 2207–2218.
- Nordlinger B, Sorbye H, Glimelius B, et al. EORTC Gastro-Intestinal Tract Cancer Group, Cancer Research UK, Arbeitsgruppe Lebermetastasen und–tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO), Australasian Gastro-Intestinal Trials Group (AGITG), Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013; 14(12): 1208–1215.
- Yaeger R, Cercek A, Chou JF, et al. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer. 2014; 120(15): 2316–2324.
- Corcoran RB, Atreya CE, Falchook GS, et al. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. J Clin Oncol. 2015; 33(34): 4023–4031.
- Kopetz S, Desai J, Chan E, et al. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. J Clin Oncol. 2015; 33(34): 4032–4038.
- Kopetz S, Grothey A, Cutsem EV, et al. Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC). J Clin Oncol. 2020; 38(15_suppl): 4001–4001.
- Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, Binimetinib, and Cetuximab in V600E-Mutated Colorectal Cancer. N Engl J Med. 2019; 381(17): 1632–1643.
- Kopetz S, Grothey A, Cutsem EV, et al. Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC). J Clin Oncol. 2020; 38(4_suppl): 8–8.
![](https://journals.viamedica.pl/plugins/generic/popups/images/icons/close.png)